Medigen Vaccine Biologics (ROCO:6547) Research & Development: NT$338.6 Mil (TTM As of Dec. 2025)


ROCO:6547 Medigen Vaccine Biologics Corp ROCO:6547
68 GF Score
Price NT$45.45
GF Value NT$69.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Medigen Vaccine Biologics Research & Development?

Medigen Vaccine Biologics ROCO:6547 -0.44% 68 Research & Development is NT$338.6 Mil as of Dec. 2025. GuruFocus rates ROCO:6547 with a GF Score™ of 68/100 and a GF Value™ of NT$69.49 (Possible Value Trap). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medigen Vaccine Biologics's Research & Development for the three months ended in Dec. 2025 was NT$166.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$338.6 Mil.

Medigen Vaccine Biologics  (ROCO:6547) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medigen Vaccine Biologics Research & Development Related Terms

Medigen Vaccine Biologics Research & Development Historical Data

* Premium members only.

The historical data trend for Medigen Vaccine Biologics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Vaccine Biologics Research & Development Chart

Medigen Vaccine Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,193.09 1,139.99 1,200.61 221.51 338.57

Medigen Vaccine Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.73 47.92 90.67 33.62 166.36
ROCO:6547
68GF Score
Medigen Vaccine Biologics Corp ROCO:6547
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Vaccine Biologics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$338.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$338.6 Mil mean?
Medigen Vaccine Biologics (ROCO:6547) has a Research & Development of NT$338.6 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Medigen Vaccine Biologics and its competitors.
Is Medigen Vaccine Biologics' Research & Development too high?
Medigen Vaccine Biologics' current Research & Development is NT$338.6 Mil. Overall, Medigen Vaccine Biologics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Research & Development compare to VRTX and REGN?
Medigen Vaccine Biologics' Research & Development of NT$338.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Research & Development is NT$338.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$69.49, compared to a current price of NT$45.45 — trading 34.6% below its estimated fair value. The current Research & Development is NT$338.6 Mil. Medigen Vaccine Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Research & Development is NT$338.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued. The current stock price of NT$45.45 is trading 34.6% below its estimated GF Value™ of NT$69.49. GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.

Key valuation signals for ROCO:6547:

  • Research & Development: NT$338.6 Mil
  • GF Value™: NT$69.49 vs. price of NT$45.45 (34.6% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Vaccine Biologics Business Description

Address 302 No. 68, Shengyi 3rd Road, Hsinchu County, Zhubei, TWN, 30261
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
68GF Score

Get the complete analysis for ROCO:6547

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$45.45
Price
NT$69.49
GF Value